An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma
The Oncologist · 27.12.2025 · 31 (1)
DOI: 10.1093/oncolo/oyaf368 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.11.2025. Verfasst von Yanrui Pang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neoadjuvant Therapy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Projects from the Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Background
The emergence of neoadjuvant immunotherapy has improved outcomes for hepatocellular carcinoma (HCC) patients, yet early postoperative recurrence remains a critical challenge. This study aimed to identify clinicopathological and immune microenvironment features associated with recurrence-free survival (RFS) and develop a predictive model for early recurrence in HCC patients undergoing neoadjuvant anti-PD-1 antibody therapy. Materials and Methods Clinicopathological characteristics and immune microenvironment profiles were analyzed in 70 HCC patients treated with neoadjuvant anti-PD-1 antibody and 20 patients receiving transarterial chemoembolization (TACE). Key variables, including microvascular invasion (MVI), tumor capsule integrity, and immune cell infiltration, were evaluated. Statistical analyses included multivariate Cox regression, Kaplan-Meier survival analysis, and nomogram construction with internal validation to predict recurrence risk.
Results
Foam cell response and tumor-infiltrating lymphocytes (TILs) were strongly linked to favorable immunotherapy responses. Patients without MVI, those with intact tumor capsules, and those exhibiting high CD4+ T cell density in central tumor regions demonstrated significantly prolonged RFS. A nomogram integrating these three factors achieved robust predictive accuracy for early recurrence stratifying patients into distinct risk groups.
Conclusions
This study highlights MVI absence, tumor capsule integrity, and CD4+ T cell infiltration as key predictors of RFS in HCC patients receiving neoadjuvant immunotherapy. The proposed nomogram provides a clinically actionable tool for early recurrence risk assessment, enabling personalized postoperative monitoring and adjuvant therapy strategies to improve survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Pathology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Förderung
- Research Projects from the Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Pang, Y., Zhao, X., Guo, X., Han, J., & Ji, Y. (2025). An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma. The Oncologist, 31(1). https://doi.org/10.1093/oncolo/oyaf368
Vancouver
Pang Y, Zhao X, Guo X, Han J, Ji Y. An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma. The Oncologist. 2025;31(1). doi:10.1093/oncolo/oyaf368
BibTeX
@article{Pang2025,
author = {Pang, Yanrui and Zhao, Xuelian and Guo, Xinxin and Han, Jing and Ji, Yuan},
title = {An early relapse prediction model based on pathological features following neoadjuvant immunotherapy for hepatocellular carcinoma},
journal = {The Oncologist},
year = {2025},
volume = {31},
number = {1},
doi = {10.1093/oncolo/oyaf368}
}
EUVIMED